Solid Tumor Testing in India Trends and Forecast
The future of the solid tumor testing market in India looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1641.7 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The solid tumor testing market in India is also forecasted to witness strong growth over the forecast period. The major drivers for this market are an increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.
• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
Emerging Trends in the Solid Tumor Testing Market in India
The Indian market for solid tumor testing is rapidly evolving owing to improvements in medical technology, increased emphasis on healthcare, and growing interest in personalized medicine. Increased attention toward precision medicine, early diagnosis, and treatment optimization is creating several new trends. These trends seek to provide more efficient and economical ways of detecting and diagnosing solid tumors, ultimately improving patient outcomes. Given below are five important trends affecting the solid tumor testing market in India.
• Increased Adoption of Liquid Biopsies: Liquid biopsy is growing in popularity in India as a more effective non-surgical solid tumor testing method compared to tissue biopsy. It also enables early-stage detection and monitoring of certain diseases via blood sampling that extracts genomic alterations and cancer-associated markers. This is critical because it enables greater comfort and reduced recovery time for patients while simultaneously providing prompt and direct diagnostic results. The growing acceptance of liquid biopsies in India is likely to enhance early cancer detection and the effectiveness of patient-tailored treatment planning in the country.
• Adoption of AI in Diagnostics Is Increasing: Artificial intelligence (AI) is positively impacting solid tumor testing in India through enhanced accuracy and rapid diagnosis. AI algorithms process a vast amount of medical data, including imaging and genomics, to find tumor patterns that may be beyond the recognition capabilities of human clinicians. AI also assists in predicting the progression of cancer and assessing the results of treatment. This contributes to a shift toward greater and faster precision diagnostics, which, in turn, ensures better patient care and more focused treatments in the Indian healthcare system.
• Movement Toward Precision Medicine: In India, the solid tumor testing market is witnessing a surge in the adoption of precision medicine with genetically specific therapies provided for solid cancers. Identifying mutations that drive cancer using advanced genomic profiling techniques allows clinicians to prescribe the best-suited therapies for individual patients. With the increasing focus of healthcare providers on precision medicine, India is moving toward specific treatments, with minimal side effects and maximum therapeutic results. This development is changing cancer treatment from simple palliative care to effective clinical management, offering better quality outcomes while decreasing the economic burden of ineffective treatments.
• Increase in the Use of Companion Diagnostics: India is adopting companion diagnostics with the same fervor as it has for targeted therapies because of how much they help in developing suitable treatment plans. These companion diagnostics are augmented through quantifiable measures, like the concentration of pregnancy-associated plasma protein-A, to gauge effectiveness. The need for these tests is a positive sign for the adoption of more precise medicine, as patients want a treatment that works and has minimal side effects in India.
• Development and Incorporation of New Imaging Methods Into MRIs and PET Scans: India is implementing the use of new imaging methods, such as MRI and PET scans, to identify solid tumors. These methods allow for early diagnosis, staging, and surveillance of tumor growth due to their clarity and detail. The acceptability of these methods is empowering cancer care specialists to better evaluate the cancer’s scope, helping make treatment strategies and improving the patient’s condition. These methods and imaging scans are expected to improve India’s entire approach to solid tumor testing as they become more affordable and easier to obtain.
Like other sectors, diagnosing solid tumors in India is seeing changes with new techniques being faster, less invasive, and more patient-specific. Market growth is propelled by liquid biopsies, AI, personalized medicine, companion diagnostics, and increased imaging modalities that enhance the accuracy of cancer detection and positively impact the quality of care that patients receive. These trends will help enhance cancer diagnosis and treatment in India, improving the overall quality of care as well as the efficiency of the healthcare system.
Recent Developments in the Solid Tumor Testing Market in India
In solid tumor testing, India has seen profound progress within the last couple of years due to technological innovations, rising cancer rates, and an increased focus on targeted therapies. The initiatives are meant to reduce the time, costs, and complexity associated with tumor testing, and India is adopting more non-invasive, accurate, and affordable diagnostic tests that are changing the paradigm in cancer treatment and detection. This section describes five critical recent developments within the cancer market in India.
• Liquid Biopsy for Early Detection: The introduction of liquid biopsy in India is a notable advancement in solid tumor testing. This blood test uses a less invasive method to analyze blood samples and target genetically mutated tumors. Liquid biopsies are preferred because they can identify tumors at earlier stages, permit a faster diagnosis, and help monitor the course of the disease. Moreover, the reduction of invasive tissue biopsy procedures also decreases discomfort and recovery time for patients. The increasingly wide use of liquid biopsies is likely to promote earlier diagnosis and treatment of cancer in a tailor-made manner throughout India.
• AI Imaging Diagnostics: Innovations in imaging AI are profoundly improving tumor testing in the country. Artificial intelligence is already making its way into radiology and pathology for more efficient and accurate analysis of medical imaging data. This AI toolkit enables the discovery of more solid tumors by recognizing more complex patterns in CT and MRI images. The incorporation of AI imaging diagnostics into the Indian health system allows diseases such as cancer to be diagnosed faster and with more accuracy, improving patient care and treatment outcomes.
• Progress Made in Genomic Profiling: Advancements in genomic profiling have completely transformed cancer treatment in India. Advanced genomic profiling has enabled specialists to pinpoint specific genetic mutations leading to solid tumors. Now oncologists can design cancer treatment plans using these advanced genomic profiling techniques. The benefits of this advancement for personalized medicine in India are immense because patients will now receive medicine specially designed for them, minimizing side effects and improving treatment outcomes.
• Government Initiatives for Cancer Care and Testing: The increase in cancer cases reported throughout the regions of India has led to certain government initiatives aimed at improving cancer care and access to solid tumor testing. The government is increasing funding for cancer research, innovative methods of testing, and infrastructural development that improves cancer care. To resolve some of these issues, government programs are also making affordable diagnostic tests available, allowing patients easy access to quality tumor testing services. All of this is beginning to lessen the burden of cancer in India.
• Cooperative Efforts between Subnational and Transnational Organizations: In India, partnerships with domestic healthcare providers are helping to improve the solid tumor testing space in oncology. These partnerships aid in the provision of information, technology, and resources, enabling Indian healthcare providers to possess modern diagnostic tools and services. Consequently, Indian patients can now receive genetic testing, advanced imaging techniques, and many other emerging innovations. Therefore, these partnerships are augmenting cancer diagnostic innovations as well as the quality of cancer care in the nation.
In India, recent changes in solid tumor testing are gradually becoming a game changer for cancer diagnosis and treatment. With the use of liquid biopsy, AI imaging, and enhanced genomic profiling, aided by supportive government policies and collaboration from international players, the efficiency, speed, and accuracy of testing services have significantly improved. These changes are making cancer care in India more effective, accurate, targeted, and efficient, which should translate to better health outcomes for patients and an enhanced healthcare system.
Strategic Growth Opportunities for Solid Tumor Testing Market in India
The solid tumor testing market in India is evolving rapidly due to the growing adoption of technology, increased awareness about precision medicine, and the rise in cancer prevalence. As a result, various components within the sector are expected to advance significantly, aiding in the enhancement of cost-effective early diagnosis and treatment of cancers. This presents particular growth potential across key industries and greatly changes the way cancer is managed. Below are five solid tumor testing opportunities in India that represent important sectors of this industry.
• Expansion in Use of Liquid Biopsy: In India, liquid biopsy has become a sensational aspect of diagnosis. Unlike conventional tissue biopsy, it is non-invasive and detects tumors in the body using blood samples. This process helps in diagnosing types of cancer that have specific genetic alterations in a more sophisticated manner. Adoption of liquid biopsies should improve early-stage cancer sensitivity and save patients from unpleasantness and protracted recovery times. There is great potential for non-invasive liquid biopsies, especially for patients with early-stage cancer due to its ease and comfort, which can improve overall survival rates in India.
• Use of AI in Tumor Detection Can Surge: India stands to benefit from the advances in technology, particularly in the testing of solid tumors. AI algorithms can process extensive imaging data and genomic information to identify patterns that human clinicians may overlook. Integrating AI into diagnostic processes can improve early-stage cancer detection, allowing for timely intervention. AI can also assist in predicting tumor progression, enabling doctors to make the most effective therapeutic decisions for individual patients. These developments can significantly impact cancer diagnosis and treatment in India.
• Improvement in Genomic Profiling Techniques: Sequencing the human genome has made it possible for people to understand the genetics of tumors. Now, tumor mutations can be specifically targeted with genomic sequencing. These therapies are much more effective than conventional methods. There have been great improvements in genomic profiling technologies, aiding in personalized medicine. Considering India has a high cancer patient population, the adoption of genomic profiling can increase treatment efficiency while reducing unnecessary side effects. While side effects are mostly inevitable with cancer medications, genomic medicine aims to decrease the potential risk. The future of oncology in India looks promising with the adoption of precision medicine along with genomic profiling.
• Expansion of Companion Diagnostics: Like other medical services, the companion diagnostics market in India is growing as it assists in identifying the right therapy for patients based on the molecular profile of their tumors. These companion diagnostic tests also help in segmenting patients for specific targeted treatments, increasing the chances of achieving desired results and reducing adverse effects. The rise in the need for individualized treatment strategies, particularly for solid tumors, is fueling the growth of companion diagnostics. Expanding the use of companion diagnostics is likely to improve the overall efficacy of cancer therapies and provide greater value for money in healthcare expenditure.
• The Rapid Expansion of Non-Invasive Imaging Techniques: Non-invasive imaging technologies such as MRI, PET, and CT scans are proving to be beneficial for the solid tumor testing market in India. These techniques enable early detection, accurate staging, and continuous monitoring of cancer, as well as providing in-depth insights into the tumors themselves. As the burden of cancer increases in India, the demand for non-invasive imaging technologies is bound to grow because such solutions improve patient comfort by lowering the need for invasive procedures. The healthcare infrastructure in India is improving, and as sophisticated imaging technologies are adopted, accurate diagnosis will improve, leading to advanced treatment planning and better outcomes.
The solid tumor testing market continues to develop rapidly in India as non-invasive liquid biopsies, AI-assisted diagnostics, genetic profiling, companion diagnostics, and sophisticated imaging techniques are integrated into practice. These opportunities are enhancing the cancer care ecosystem by enabling more accurate, targeted, and non-invasive treatment options. With further advancement in these technologies, there will be tremendous improvements in the efficiency of early cancer detection, treatment optimization, patient prognosis, and the overall healthcare system and cancer management in India.
Solid Tumor Testing Market in India Driver and Challenges
The solid tumor testing market in India is influenced by multiple factors, including technology, the economy, and regulations. Important drivers like innovations in technology, the rising number of cancer cases, and the better functioning of the healthcare system are propelling market growth. On the other hand, challenges such as high costs, strict regulations, and lack of adequate infrastructure remain. It is important to understand these drivers and challenges to measure potential market growth and develop strategies to overcome obstacles. This analysis looks into the solid tumor testing market in India and all the major drivers and challenges it entails.
The factors responsible for driving the solid tumor testing market in India include:
• Improvement in Technology: Solid tumor testing has greatly benefited from technological improvements. New technologies like liquid biopsy, AI-based diagnostics, and genomic profiling allow for much faster and more accurate tumor detection, which drastically improves patient outcomes. These technologies offer the possibility of diagnosing cancer at an early stage, enabling advanced treatment and complete control of the tumor’s stage. As more healthcare providers in India utilize these advanced technologies, the market is predicted to grow. The combination of AI, genomic profiling, and treating cancer patients with precision medicine represents the future of medicine, reducing unnecessary harm and improving overall outcomes.
• Increasing Cases of Cancer: The growth of the solid tumor testing market is driven by several factors, including the increasing volume of cancer cases in India. Due to urbanization and an aging population, India is experiencing an increase in cancer cases, and along with this change, lifestyle shifts are adding to the problem. All these factors have put a strain on the healthcare system, demanding more efficient and accurate diagnostic solutions. Therefore, there is an urgent need for reliable tumor testing methods that can identify cancer at early stages for effective management. The increased prevalence of cancer has also necessitated the use of more sophisticated diagnostic methods, which, in turn, enhances the growth of the solid tumor testing market.
• Government Initiatives and Healthcare Investment: The rapid rise of cancer cases has been addressed by the Indian government through investments in much-needed cancer infrastructure, research, and modern cancer diagnostics. Along with these initiatives, there are policies focused on providing greater access to quality healthcare, which in turn supports the need for solid tumor testing tools. These policies are beneficial for aiding financial support for advanced cancer diagnostic tools and treatments due to the collaboration between private and public entities, which allows for better techniques to be introduced in cancer research. As a result, these programs will enhance the availability of cancer care in India and subsequently improve access to solid tumor testing among patients who need it.
• Increasing Healthcare Attention: A growing concern in the Indian market is the awareness about cancer prevention, treatment, and early detection. The public is becoming more educated about the importance of early diagnosis and the availability of advanced testing methods, including liquid biopsy and genetic profiling. Awareness campaigns, along with access to healthcare information, have motivated people toward regular screenings and tests. This growing shift toward proactive healthcare is increasing the demand for solid tumor testing services, which, in turn, is contributing to the market’s growth.
• Healthcare Shift Toward Patients: In India, the move toward personalized medicine is transforming the landscape of solid tumor testing. Tailored or precision medicine, which adjusts treatment according to a patient’s genetics, is on the rise. With newer techniques in genomic profiling and companion diagnostics, India is embracing new therapies that target specific genetic mutations in tumors. As it increases the effectiveness of treatment while minimizing side effects, it also improves the patients’ quality of life and health. The surge in the offering and receiving of personalized medicine is greatly benefiting the solid tumor testing market, as patients increasingly demand specific treatment options.
Challenges in the solid tumor testing market in India are:
• Obstacles Posed by Sophisticated Testing Method Expenses: One of the challenges of the solid tumor testing market is the high costs associated with advanced diagnostic technologies. Technologies such as liquid biopsy, genomic profiling, and AI-powered tools come at a premium and are only available at the most elite healthcare facilities. Because of this, a significant portion of the population, especially in rural and underdeveloped regions, does not have access to these advanced testing facilities. The high cost of these testing procedures not only restricts growth in the market but also widens the gap in cancer care inequality that exists between regions, making expansion difficult.
• Diagnosis Technique Regulation Issues and Examination Period Expansions: The solid tumor testing market in India is also affected by regulatory issues, including the slow approval of new diagnostic tools for wider use within the health sector. The adoption of more sophisticated tests and techniques, like liquid biopsies or AI diagnostics, requires testing them on large clinical populations and obtaining the necessary regulatory approvals, which could take years for them to be accepted. Slower regulatory measures result in less innovation being fostered and greater reluctance among health providers to deploy new technologies when they are available. Furthermore, differing policies from one area to another could obstruct the growth and advancement of the country in various areas.
• Infrastructure Gaps in Healthcare Delivery: India has one of the fastest-growing healthcare infrastructures, but there are significant challenges that hinder access to solid tumor testing, especially in rural areas. Many regions lack appropriate facilities, trained staff, and equipment to perform advanced diagnostic tests, which ultimately leads to delays in the critical diagnosing stage and can interfere with treatment outcomes. Remote regions face a confluence of a lack of skilled labor and insufficient diagnostic centers, making it more difficult to meet cancer diagnostic needs. These disparities in infrastructure must be addressed if solid tumor testing is to be made accessible across India.
In India, the solid tumor testing market is expanding due to technological improvements, high rates of cancer, and government support. On the other hand, the market’s expansion is negatively impacted by costs, regulatory bottlenecks, and infrastructural neglect. Although these are hurdles, profitability can be achieved by focusing on proper infrastructure for early cancer diagnosis, treatment efficiency, and overall healthcare improvement in India. Proper planning needs to be focused on those key drivers and challenges that will help the country solidify its cancer testing and care accessibility.
List of Solid Tumor Testing Market in India Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, solid tumor testing companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Solid Tumor Testing Market in India by Segment
The study includes a forecast for the solid tumor testing market in India by type, application, and end use.
Solid Tumor Testing Market in India by Type [Analysis by Value from 2019 to 2031]:
• Genetic Testing
• Conventional Testing
Solid Tumor Testing Market in India by Application [Analysis by Value from 2019 to 2031]:
• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others
Solid Tumor Testing Market in India by End Use [Analysis by Value from 2019 to 2031]:
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions
Features of the Solid Tumor Testing Market in India
Market Size Estimates: Solid tumor testing in India market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Solid tumor testing in India market size by type, application, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, application, and end use for the solid tumor testing in India.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing in India.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the solid tumor testing market in India?
Answer: The major drivers for this market are increase in the utilization of supplements and steroids and increase in unhealthy habits, such as smoking and alcohol consumption.
Q2. What are the major segments for solid tumor testing market in India?
Answer: The future of the solid tumor testing market in India looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets.
Q3. Which solid tumor testing market segment in India will be the largest in future?
Answer: Lucintel forecasts that melanoma is expected to witness the highest growth over the forecast period due to growing incidence of skin tumors and related conditions globally.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market in India by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), and end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Solid Tumor Testing Market in India, Solid Tumor Testing Market in India Size, Solid Tumor Testing Market in India Growth, Solid Tumor Testing Market in India Analysis, Solid Tumor Testing Market in India Report, Solid Tumor Testing Market in India Share, Solid Tumor Testing Market in India Trends, Solid Tumor Testing Market in India Forecast, Solid Tumor Testing Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.